For US residents only.

Understanding Treatment

TAFINLAR + MEKINIST

Is TAFINLAR + MEKINIST right for me?

TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets is a combination therapy for BRAF-positive (also seen as BRAF+) melanoma. TAFINLAR + MEKINIST is a targeted therapy that can be used as treatment for 2 different types of melanoma:

  • Adjuvant (after surgery) treatment of BRAF+ melanoma, to help prevent your melanoma from coming back after surgery
  • Treatment of metastatic BRAF+ melanoma that has spread to other parts of the body (eg, the liver, lungs, or brain) and cannot be removed by surgery, to help slow progression of your melanoma

How does TAFINLAR + MEKINIST treat my melanoma?

Medical research has shown that TAFINLAR + MEKINIST may help slow the growth of certain melanoma cancer cells with a BRAF mutation. TAFINLAR + MEKINIST has been studied in clinical trials of patients with BRAF+ melanoma (either V600E or V600K mutation-positive as determined by a US Food and Drug Administration [FDA]-approved test).

 

Your health care provider will only prescribe you TAFINLAR + MEKINIST after a genetic test is performed on a biopsy (sample of tissue taken for further testing) of your melanoma with a positive result indicating a BRAF mutation. When discussing treatment options with your health care provider, ask if genetic testing for BRAF mutations is right for you.

What kind of treatment is TAFINLAR + MEKINIST?

As a targeted combination therapy, TAFINLAR + MEKINIST helps inhibit out-of-control cell growth by blocking cell-growth signals associated with the BRAF gene. TAFINLAR and MEKINIST work together, with each targeting a different point in this cell-signaling pathway. Treatment can also affect healthy cells in the body. 

 

TAFINLAR + MEKINIST is a combination targeted therapy that can be used as adjuvant (after surgery) treatment of BRAF+ melanoma or as treatment for BRAF+ metastatic or inoperable melanoma.